Hi Harsh,
Assuming the sgRNA is well-designed to target a specific site, the Cas9 should only modify that site but, as demonstrated in several papers, Cas9 can cut at a lower frequency at an off-target site. Since lentiviral expression under a constitutive promoter results in continual Cas9 expression, it may modify several others sites as more and more time passes.
For making a clonal cell line that will be used in downstream assays, I think it is better to avoid lentiviral Cas9 and use transient delivery (e.g. transfection of DNA/RNA, protein delivery, microinjection, etc.) Lentiviral Cas9 is better suited to applications like high-throughput screening, where you have a readout that occurs within days to a few weeks after genome modification.
Hope that helps,
Neville